The Stern Cardiovascular Center Receives Accreditation
from the Intersocietal Commission for the
Accreditation of Nuclear Medicine Laboratories (ICANL)
Germantown, TN -- The Stern Cardiovascular Center has been chosen as a site for the PEERLESS-HF (Prospective Evaluation of Elastic Restraint to LESSen the effects of Heart Failure) clinical research study, according to Frank A. McGrew III, MD, principal investigator.
The American Heart Association and the Heart Failure Society of America estimate that 5 million Americans have been diagnosed with heart failure — and that as many as 500,000 new heart failure diagnoses are made annually. Heart failure is reported to be the cause or a leading contributor to over 300,000 deaths in the U.S. each year.
Paracor Medical, Inc., of Sunnyvale , CA is the sponsor of the clinical research study to evaluate its HeartNet™ therapy. The HeartNet implant is delivered in a less-invasive surgical procedure that can typically be completed in less than 90 minutes. This elastic device provides continuous support to the walls of the heart's pumping chambers, the ventricles. It is the intent of HeartNet to stop or control further enlargement of the heart and alleviate the symptoms of advanced heart failure, which can include extreme fatigue, swelling in the extremities and shortness of breath.